DOFETILIDE PACKAGE INSERT PDF
Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||15 February 2005|
|PDF File Size:||12.20 Mb|
|ePub File Size:||14.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
Osimertinib causes concentration dependent prolongation of the QT interval at recommended dosing. Major Coadministration of CYP3A4 inhibitors, such as nelfinavir, with dofetilide may decrease the metabolism of dofetilide, thereby increasing the potential for QT prolongation. Because of the unpredictable pharmacokinetics of amiodarone, dofetilide should not be initiated following a Quinine: Severe QT prolongation and ventricular arrhythmias, including torsade de pointes TdP and death, have been reported with cisapride.
Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with dalfopristin; quinupristin is necessary.
Clinical trial data indicate that ziprasidone causes QT prolongation; apckage are postmarketing reports of TdP in patients with multiple confounding factors. Moderate Theoretically, bosentan can induce the hepatic metabolism of dofetilide via CYP3A4 isoenzymes.
Severe The concomitant use of erythromycin and dofetilide is contraindicated. Toremifene has also been shown to prolong the QTc interval in a dose- and concentration-related manner.
Major Coadministration of CYP3A4 inhibitors, such as atazanavir, with dofetilide may decrease the metabolism of dofetilide, thereby increasing the potential for QT inserg.
Lamivudine; Tenofovir Disoproxil Fumarate: If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Tikosyn (dofetilide) dose, indications, adverse effects, interactions from
Increased concentrations of dofetilide may increase the risk for side effects including proarrhythmia. The OBRA guidelines caution that antiarrhythmics can have serious adverse effects e. Dialysis, renal disease, renal failure, renal impairment. Post-marketing surveillance for ofloxacin has identified very rare cases of torsades de pointes TdP.
Severe Because of the potential for TdP, concurrent use of mifepristone and dofetilide is contraindicated. Androgen deprivation therapy e.
The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. Severe Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics and thiazide diuretics, increasing the potential for dofetilide-induced torsade de pointes. The increase in QT interval observed on the ECG is a result of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles.
Major Monitor for an increase in dofetilide-related adverse effects, including QT prolongation and torsade de pointes TdPif coadministered with duvelisib. The oral bioavailability is unaffected by food or antacids.
Severe Because of the potential for torsades de pointes TdPconcurrent use of dofetilide and crizotinib is contraindicated. Because of the potential for TdP, use with other drugs that prolong the QT interval, such as quinine, is contraindicated. Erythromycin administration is associated with QT prolongation and TdP. Because of the potential for TdP, use of dofetilide with pimozide is contraindicated. Because of the potential for TdP, use of dofetilide with pazopanib is contraindicated.
Severe There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. According to the manufacturer, propafenone antiarrhythmic agents is associated with QT prolongation and ventricular arrhythmias and concurrent exposure with dofetilide could increase the risk of dofetilide-induced proarrhythmias. Severe Lithium has been associated with QT prolongation. Severe Because of the potential for torsades de pointes TdPuse of tolterodine and dofetilide is contraindicated.
Plasma dofetilide concentrations are correlated with the risk of drug-induced proarrhythmias. Grapefruit juice contains furanocoumarins that are metabolized by CYP3A4 to reactive intermediates.
Major Dofetilide should be co-administered with tenofovir alafenamide with caution since both drugs are actively secreted via cationic secretion and could compete for common renal tubular transport systems. Severe Dlfetilide of the potential for torsade de pointes TdPuse of histrelin with dofetilide is contraindicated.
Because of the potential for TdP, use of dofetilide with romidepsin is contraindicated. Severe Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations.
Severe Concurrent use of isavuconazonium with dofetilide is contraindicated due to the potential for increased dofetilide exposure resulting in serious and life-threatening adverse events, such as QT prolongation and torsade de pointes TdP. Because of the potential for TdP, use of atomoxetine with unsert is contraindicated. Careful patient monitoring and packqge adjustment of dofetilide is recommended. Coadministration of pasireotide and drugs that prolong the QT interval may have additive effects on the prolongation of the QT interval.